Abstract
Ibrutinib is a Bruton's Tyrosine Kinase Inhibitor indicated for the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM). Medical resource utilization (MRU) and associated costs for patients treated with ibrutinib in France in real-life settings are unknown and need to be examined.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
